Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

There has never been "plenty of overseas interest."

DR-70 had dismal sales globally since its inception. The excuse was always "as soon as they get FDA clearance, overseas sales will skyrocket." Unfortunately, that was proven wrong.

Radient did seem to have modest success selling onko-sure in Asia. Revenues were still only about 5% of operating costs, but what little they DID sell was mostly in Asia.

The bad news there is: Radient just gave away Asia sales to UNI, for a license fee of $100 per year.

So I fail to see the potential.